TLSITriSalus Life Sciences, Inc.

Nasdaq trisaluslifesci.com


$ 5.33 $ 0.01 (0.19 %)    

Friday, 30-Aug-2024 15:58:05 EDT
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 5.25
$ 5.14 x 100
$ 5.49 x 100
-- - --
$ 3.32 - $ 10.42
34,237
na
153.89M
$ 0.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-11-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-02-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 06-28-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trisalus-life-sciences-q2-2024-gaap-eps-021-beats-041-estimate-sales-736m-inline

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate o...

 canaccord-genuity-maintains-buy-on-trisalus-life-sciences-maintains-12-price-target

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $12 price...

 trisalus-life-sciences-presents-liver-and-pancreatic-cancer-data-at-asco-2024

TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) t...

 canaccord-genuity-initiates-coverage-on-trisalus-life-sciences-with-buy-rating-announces-price-target-of-12

Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and ...

 trisalus-life-sciences-q1-2024-gaap-eps-060-beats-065-estimate-sales-6457m-beat-6178m-estimate

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate o...

 jonestrading-initiates-coverage-on-trisalus-life-sciences-with-buy-rating-announces-price-target-of-16

JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces...

 trisalus-life-sciences-secures-up-to-50m-of-debt-financing-with-orbimed-to-support-trinav-infusion-system-growth-initiatives

$25 million funded at close; up to $25 million of additional capital available at the Company's option, based on the achiev...

 trisalus-life-sciences-q4-2023-gaap-eps-156-misses-069-estimate-sales-5721m-beat-5453m-estimate

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-april-1-2024

Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per...

 trisalus-life-sciences-expects-sales-to-grow-in-excess-of-50-in-2024-says-currently-in-the-process-of-obtaining-additional-liquidity-to-fund-operations-through-2024

TriSalus also expects to report cash and cash equivalents balances of approximately $11.8 million as of December 31, 2023. It e...

 trisalus-life-sciences-reports-preliminary-q4-sales-of-approximately-57m-representing-77-growth-versus-2022-est-5453m

For the full year 2023, TriSalus expects to report revenue of approximately $18.5 million. This represents growth of approximat...

 earnings-scheduled-for-november-14-2023

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION